Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation

M. Benešová, K. Trejbalová, D. Kučerová, Z. Vernerová, T. Hron, A. Szabó, R. Amouroux, P. Klézl, P. Hajkova, J. Hejnar,

. 2017 ; 56 (8) : 1837-1850. [pub] 20170524

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031025

Germ cell tumors and particularly seminomas reflect the epigenomic features of their parental primordial germ cells (PGCs), including genomic DNA hypomethylation and expression of pluripotent cell markers. Because the DNA hypomethylation might be a result of TET dioxygenase activity, we examined expression of TET1-3 enzymes and the level of their product, 5-hydroxymethylcytosine (5hmC), in a panel of histologically characterized seminomas and non-seminomatous germ cell tumors. Expression of TET dioxygenase mRNAs was quantified by real-time PCR. TET1 expression and the level of 5hmC were examined immunohistochemically. Quantitative assessment of 5-methylcytosine (5mC) and 5hmC levels was done by the liquid chromatography-mass spectroscopy technique. We found highly increased expression of TET1 dioxygenase in most seminomas and strong TET1 staining in seminoma cells. Isocitrate dehydrogenase 1 and 2 mutations were not detected, suggesting the enzymatic activity of TET1. The levels of 5mC and 5hmC in seminomas were found decreased in comparison to non-seminomatous germ cell tumors and healthy testicular tissue. We propose that TET1 expression should be studied as a potential marker of seminomas and mixed germ cell tumors and we suggest that elevated expression of TET dioxygenase enzymes is associated with the maintenance of low DNA methylation levels in seminomas. This "anti-methylator" phenotype of seminomas is in contrast to the CpG island methylator phenotype (CIMP) observed in a fraction of tumors of various types.

000      
00000naa a2200000 a 4500
001      
bmc17031025
003      
CZ-PrNML
005      
20171102113231.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mc.22638 $2 doi
035    __
$a (PubMed)28218476
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benešová, Martina $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
245    10
$a Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation / $c M. Benešová, K. Trejbalová, D. Kučerová, Z. Vernerová, T. Hron, A. Szabó, R. Amouroux, P. Klézl, P. Hajkova, J. Hejnar,
520    9_
$a Germ cell tumors and particularly seminomas reflect the epigenomic features of their parental primordial germ cells (PGCs), including genomic DNA hypomethylation and expression of pluripotent cell markers. Because the DNA hypomethylation might be a result of TET dioxygenase activity, we examined expression of TET1-3 enzymes and the level of their product, 5-hydroxymethylcytosine (5hmC), in a panel of histologically characterized seminomas and non-seminomatous germ cell tumors. Expression of TET dioxygenase mRNAs was quantified by real-time PCR. TET1 expression and the level of 5hmC were examined immunohistochemically. Quantitative assessment of 5-methylcytosine (5mC) and 5hmC levels was done by the liquid chromatography-mass spectroscopy technique. We found highly increased expression of TET1 dioxygenase in most seminomas and strong TET1 staining in seminoma cells. Isocitrate dehydrogenase 1 and 2 mutations were not detected, suggesting the enzymatic activity of TET1. The levels of 5mC and 5hmC in seminomas were found decreased in comparison to non-seminomatous germ cell tumors and healthy testicular tissue. We propose that TET1 expression should be studied as a potential marker of seminomas and mixed germ cell tumors and we suggest that elevated expression of TET dioxygenase enzymes is associated with the maintenance of low DNA methylation levels in seminomas. This "anti-methylator" phenotype of seminomas is in contrast to the CpG island methylator phenotype (CIMP) observed in a fraction of tumors of various types.
650    _2
$a 5-methylcytosin $x analogy a deriváty $x analýza $7 D044503
650    _2
$a dospělí $7 D000328
650    12
$a metylace DNA $7 D019175
650    _2
$a DNA vazebné proteiny $x analýza $x genetika $7 D004268
650    _2
$a dioxygenasy $x analýza $x genetika $7 D049308
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxygenasy se smíšenou funkcí $x analýza $x genetika $7 D006899
650    _2
$a protoonkogenní proteiny $x analýza $x genetika $7 D011518
650    _2
$a seminom $x genetika $x patologie $7 D018239
650    _2
$a testikulární nádory $x genetika $x patologie $7 D013736
650    _2
$a testis $x metabolismus $x patologie $7 D013737
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Trejbalová, Kateřina $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
700    1_
$a Kučerová, Dana $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
700    1_
$a Vernerová, Zdenka $u Department of Pathology, Third Faculty of Medicine, Charles University in Prague, Ruska 87, CZ-10000, Prague 10, Czech Republic.
700    1_
$a Hron, Tomáš $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
700    1_
$a Szabó, Arpád $u Department of Pathology, Third Faculty of Medicine, Charles University in Prague, Ruska 87, CZ-10000, Prague 10, Czech Republic.
700    1_
$a Amouroux, Rachel $u MRC London Institute of Medical Sciences, London, UK and Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, UK. $7 gn_A_00005734
700    1_
$a Klézl, Petr $u Department of Urology, Third Faculty of Medicine, Charles University in Prague, Ruska 87, CZ-10000, Prague 10, Czech Republic.
700    1_
$a Hajkova, Petra $u MRC London Institute of Medical Sciences, London, UK and Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, UK.
700    1_
$a Hejnar, Jiří $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, CZ-14220 Prague 4, Czech Republic.
773    0_
$w MED00188779 $t Molecular carcinogenesis $x 1098-2744 $g Roč. 56, č. 8 (2017), s. 1837-1850
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28218476 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171102113324 $b ABA008
999    __
$a ok $b bmc $g 1254618 $s 992052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 56 $c 8 $d 1837-1850 $e 20170524 $i 1098-2744 $m Molecular carcinogenesis $n Mol Carcinog $x MED00188779
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace